Expert insight 15 Nov 2022

Renewing industry’s commitment to better access to diabetes care on World Diabetes Day

This World Diabetes Day (WDD), IFPMA and its members are renewing our commitment to take proactive steps to improve access to diabetes care and make progress toward the achievement of SDG target 3.4.

Read more
Statement 28 Oct 2022

IFPMA Response to the Release of the ACT-A Evaluation Report

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) was a founding member of ACT-A when it was launched in April 2020. We welcomed the vision of the ACT-A to involve the private sector, including the innovative pharmaceutical industry, to join this unique global collaboration set up to accelerate development, production, and equitable access to...

Read more
Statement 27 Oct 2022

IFPMA statement at the 73rd session of the WHO Regional Committee for Western Pacific: Items recommended by the World Health Assembly and the Executive Board

IFPMA welcomes the opportunity to make this statement and to share our Covid-19 Lessons Learned, which highlights that swift pathogen surveillance and sharing, an enabling innovation ecosystem, and regulatory agility must be preserved to ensure our collective ability to fight against unknown diseases.

Read more
Statement 27 Oct 2022

IFPMA statement at the 73rd session of the WHO Regional Committee for Western Pacific: Noncommunicable disease prevention and control

IFPMA appreciates the opportunity to make this statement. The ongoing fight against COVID-19 has shown that those with chronic conditions and co-morbidities are often the most vulnerable and have suffered the most throughout the pandemic.

Read more
Position paper 25 Oct 2022

Principles for a fit-for-purpose global health architecture

Biopharmaceutical industry’s considerations on key elements for an effective multilateral Pandemic Prevention, Preparedness, and Response (PPR) instrument.

Read more
Press release 23 Oct 2022

Biotechs, developing countries vaccine manufacturers and pharma unite behind a proposal to G20 and G7 offering a practical solution for better access to vaccines for future pandemics

The vaccines innovators and manufacturers who have produced over 15 billion COVID-19 vaccines to date are making a proposal that would ensure new vaccines developed for future global pandemics would reach all priority populations equally, wherever they live, thereby addressing a key element of vaccine inequity that hampered the roll out of COVID-19 vaccines in...

Read more
Report 19 Oct 2022

IFPMA COVID-19 Innovation Timeline

This timeline illustrates how the innovative pharmaceutical industry came together with the broader global health community to respond to the COVID-19 pandemic with unprecedented speed and scale, overcoming significant hurdles along the way.

Read more
Statement 18 Oct 2022

IFPMA statement at the 69th session of the WHO EMRO committee on agenda item EM/RC69/14

IFPMA welcomes the opportunity to provide comments in relation to this agenda item. The global community needs to look ahead to how it can learn from current experience of COVID-19 and design a new global architecture for Health Emergency Preparedness, Response and Resilience. The IFPMA Covid-19 Lessons Learned report highlights some of the key factors...

Read more
Expert insight 13 Oct 2022

Is an extension of the TRIPS waiver needed for COVID-19 tools?

Evidence shows that progress made in sharing IP through voluntary agreements, combined with tiered-pricing and not-for-profit arrangements for low- and middle-income countries has led to production of COVID-19 therapeutics exceeding demand for all disease severity levels and in all patient settings.

Read more
Expert insight 3 Oct 2022

Innovative partnership model to improve access to cancer care in LMICs

Through public and private sector partnerships, a global initiative innovates for better access to cancer care worldwide.

Read more
Statement 28 Sep 2022

IFPMA statement at the 74th session of the WHO Regional Committee for the Americas on the COVID-19 pandemic in the region of the Americas

28 September 2022, Washington, DC, USA — IFPMA welcomes the opportunity to share our from Covid-19 Lessons Learned, which highlights that swift pathogen surveillance and sharing, an enabling innovation ecosystem, and regulatory agility must be preserved to ensure our collective ability to fight against unknown diseases. The most important lesson of the report is that...

Read more
Statement 28 Sep 2022

IFPMA Statement at the WHO Second Public Hearings to support the intergovernmental negotiating body to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response

Delivered by: Thomas Cueni, Director General, International Federation of Pharmaceutical Manufacturers & Associations Based on your experience with the COVID-19 pandemic, what do you believe should be addressed at the international level to better protect against future pandemics?” While we have been part of the largest and most rapid global vaccine rollout in history, we...

Read more